BR112022005013A2 - Imageamento direcionado à proteína de ativação de fibroblasto (fap) e terapia de cânceres e outras doenças inflamatórias e fibróticas - Google Patents
Imageamento direcionado à proteína de ativação de fibroblasto (fap) e terapia de cânceres e outras doenças inflamatórias e fibróticasInfo
- Publication number
- BR112022005013A2 BR112022005013A2 BR112022005013A BR112022005013A BR112022005013A2 BR 112022005013 A2 BR112022005013 A2 BR 112022005013A2 BR 112022005013 A BR112022005013 A BR 112022005013A BR 112022005013 A BR112022005013 A BR 112022005013A BR 112022005013 A2 BR112022005013 A2 BR 112022005013A2
- Authority
- BR
- Brazil
- Prior art keywords
- fap
- imaging
- inflammatory
- cancers
- therapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 210000002950 fibroblast Anatomy 0.000 title abstract 3
- 238000003384 imaging method Methods 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 230000003213 activating effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000003176 fibrotic effect Effects 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
imageamento direcionado à proteína de ativação de fibroblasto (fap) e terapia de cânceres e outras doenças inflamatórias e fibróticas. compostos de direcionamento para proteína de ativação de fibroblasto (fap) (por exemplo, conjugados); um método para imagear câncer ou fibrose; e métodos para tratar um distúrbio/doença inflamatória e câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962901792P | 2019-09-17 | 2019-09-17 | |
PCT/US2020/051328 WO2021055641A1 (en) | 2019-09-17 | 2020-09-17 | Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022005013A2 true BR112022005013A2 (pt) | 2022-06-21 |
Family
ID=74883518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022005013A BR112022005013A2 (pt) | 2019-09-17 | 2020-09-17 | Imageamento direcionado à proteína de ativação de fibroblasto (fap) e terapia de cânceres e outras doenças inflamatórias e fibróticas |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220409747A1 (pt) |
EP (1) | EP4031184A4 (pt) |
JP (1) | JP2022548155A (pt) |
KR (1) | KR20220066098A (pt) |
CN (1) | CN114901315A (pt) |
AU (1) | AU2020348781A1 (pt) |
BR (1) | BR112022005013A2 (pt) |
CA (1) | CA3150890A1 (pt) |
IL (1) | IL291386A (pt) |
MX (1) | MX2022003215A (pt) |
WO (1) | WO2021055641A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110582288A (zh) | 2017-02-28 | 2019-12-17 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
BR112020014913A2 (pt) | 2018-01-22 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Métodos para uso de células t car |
EP4132921A4 (en) * | 2020-04-09 | 2024-03-27 | Purdue Research Foundation | PI3 KINASE INHIBITORS AND THEIR USES |
WO2023244828A1 (en) * | 2022-06-17 | 2023-12-21 | Purdue Research Foundation | Fibroblast activation protein-targeted nanoparticle magnetic resonance imaging agents |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071787B2 (en) * | 2009-03-13 | 2011-12-06 | National Health Research Institutes | Pyrrolidine compounds |
CN103788071A (zh) * | 2012-11-01 | 2014-05-14 | 中国人民解放军第二军医大学 | N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途 |
JP6853193B2 (ja) * | 2016-01-29 | 2021-03-31 | 協和キリン株式会社 | 核酸複合体 |
CN116474108A (zh) * | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
EA202090776A1 (ru) * | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
AU2018392213B2 (en) * | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
WO2019154859A1 (en) * | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
DE102018126558A1 (de) * | 2018-10-24 | 2020-04-30 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Markierungsvorläufer mit Quadratsäure-Kopplung |
-
2020
- 2020-09-17 WO PCT/US2020/051328 patent/WO2021055641A1/en unknown
- 2020-09-17 AU AU2020348781A patent/AU2020348781A1/en active Pending
- 2020-09-17 US US17/761,508 patent/US20220409747A1/en active Pending
- 2020-09-17 JP JP2022517166A patent/JP2022548155A/ja active Pending
- 2020-09-17 BR BR112022005013A patent/BR112022005013A2/pt unknown
- 2020-09-17 EP EP20865602.5A patent/EP4031184A4/en active Pending
- 2020-09-17 CN CN202080079485.1A patent/CN114901315A/zh active Pending
- 2020-09-17 KR KR1020227012076A patent/KR20220066098A/ko unknown
- 2020-09-17 MX MX2022003215A patent/MX2022003215A/es unknown
- 2020-09-17 CA CA3150890A patent/CA3150890A1/en active Pending
-
2022
- 2022-03-15 IL IL291386A patent/IL291386A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL291386A (en) | 2022-05-01 |
US20220409747A1 (en) | 2022-12-29 |
EP4031184A1 (en) | 2022-07-27 |
CN114901315A (zh) | 2022-08-12 |
CA3150890A1 (en) | 2021-03-25 |
KR20220066098A (ko) | 2022-05-23 |
AU2020348781A1 (en) | 2022-04-14 |
MX2022003215A (es) | 2022-04-25 |
WO2021055641A1 (en) | 2021-03-25 |
EP4031184A4 (en) | 2023-12-06 |
JP2022548155A (ja) | 2022-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022005013A2 (pt) | Imageamento direcionado à proteína de ativação de fibroblasto (fap) e terapia de cânceres e outras doenças inflamatórias e fibróticas | |
EA202090776A1 (ru) | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) | |
CY1124435T1 (el) | Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α | |
MX2020010458A (es) | Conjugados de camptotecina-peptido. | |
PH12019502545A1 (en) | Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate | |
MX2019011148A (es) | Metodos de tratamiento. | |
EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
CY1123043T1 (el) | Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων | |
UY33254A (es) | Proteínas terapéuticas de unión a dll4 | |
MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
BR112022002837A2 (pt) | Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo | |
BR112021024463A2 (pt) | Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas | |
BR112022015416A2 (pt) | Anticorpos anti-ror1 e composições | |
MX2021009239A (es) | Tratamiento contra el cáncer con inmunoconjugados de anticuerpos ror1. | |
BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
ATE526037T1 (de) | Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen | |
CL2021001593A1 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
BR112021017303A2 (pt) | Conjugado de anticorpo ou um sal ou solvato farmaceuticamente aceitável deste, anticorpo que se liga com especificidade ao dlk1 ou um fragmento de ligação ao antígeno deste, composição farmacêutica para prevenção ou tratamento de doença proliferativa, câncer ou angiogênica, métodos para prevenção e para tratamento de doença proliferativa, câncer ou angiogênica, e, uso do conjugado | |
MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
BR112022026236A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr | |
AR104484A1 (es) | Anticuerpos anti-psma como agentes terapéuticos | |
EA202092540A1 (ru) | Комбинации для лечения рака | |
CO6382138A2 (es) | N-cadherina: blanco para diagnosis y terapia de cáncer | |
BR112021017550A2 (pt) | Métodos de tratamento da amiloidose al | |
CL2022001970A1 (es) | Conjugados de proteínas-compuestos antivirales |